Brepocitinib Skin Outcomes in Patients With Dermatomyositis

Save

A secondary analysis of the VALOR trial has shown that the TYK2/JAK1 inhibitor brepocitinib was effective at cutaneous disease activity outcomes, delivering rapid, clinically meaningful, and remission-level control of cutaneous dermatomyositis (DM).

JAMA Review: Postural Orthostatic Tachycardia Syndrome (POTS)

Save

Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder affecting an estimated 0.1%–1% of the US population, with peak incidence at ages 13–29 and a striking 90% female predominance.

Age-specific Incidence of Systemic Lupus Erythematosus

Save

Guidelines for Adult-Onset IgA Vasculitis

Save

A EUVAS-sponsored expert panel of 37 specialists across rheumatology, nephrology, dermatology and pathology has published evidence-based guidelines for adult-onset IgA vasculitis (IgAV), which behaves very differently in adults compared to usually self-limited childhood form.

Registry Data Shows Liver Risk With Avacopan

Save

A new study may add fuel to the fire already burning around avacopan (Tavneos), approved in 2021 to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), which the FDA wants drugmaker Amgen to pull from the U.S. market.

Glucocorticoids: Use vs.Toxicity

Save

This review article addresses the recognition, prevention and management of glucocorticoid toxicity in rheumatic patients.

A Tribute to Thomas A. Medsger Jr., MD (1936–2026)

Save

The rheumatology and scleroderma communities mourn the loss of Dr. Thomas A. Medsger Jr., who died August 15, 2026, in Pittsburgh, at age 89.

Risk of Venous Thromboembolism in Rheumatoid Arthritis

Save

RA confers a 50–100% excess risk of venous thromboembolism (VTE) compared with the general population, with adjusted hazard/odds ratios ranging from 1.3–2.2 across large cohort studies (Vojinovic, Askling, Antovic; Rheumatology, 2026).